Allakos Inc (ALLK)

109.18
+3.41(+3.22%)
After Hours
110.01
+0.83(+0.76%)
- Real-time Data
  • Volume:
    361,393
  • Bid/Ask:
    108.36/111.00
  • Day's Range:
    105.42 - 109.95

ALLK Overview

Prev. Close
105.77
Day's Range
105.42-109.95
Revenue
-
Open
106.65
52 wk Range
75.41-157.98
EPS
-3.83
Volume
361,393
Market Cap
5.9B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
271,954
P/E Ratio
-
Beta
-
1-Year Change
34.41%
Shares Outstanding
53,996,459
Next Earnings Date
Nov 16, 2021
What is your sentiment on Allakos Inc?
or
Market is currently closed. Voting is open during market hours.

Allakos Inc News

  • Allakos EPS in-line
    • BySeeking Alpha-

    Allakos (ALLK): Q2 GAAP EPS of -$1.07 in-line.Allakos ended the second quarter of 2021 with $559.7 million in cash, cash equivalents and marketable securities.Press Release

Allakos Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Allakos Inc Company Profile

Allakos Inc Company Profile

Employees
151

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.

Read More
  • what is going on Allk? is there anybody share sth about sharp loos after booming?
    0
    • Allakos  have served as its own contract research organization (CRO) it is like a company serving as its own auditor, or a fund serving as its own administrator.
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.